Introduction
Allogeneic haematopoietic cell transplantation (HCT) is associated with serious and debilitating long-term problems, many of which involve the oral tissues and/or salivary glands. Of these, the most significant is chronic GVHD (cGVHD), which occurs in 40-70% of survivors of HCT and may involve the oral cavity as the principal or sole site of involvement, in 50-83% of those affected. 1 Oral cGVHD may present in many different ways, with 'diagnostic presentations' of oral cGVHD identified by the NIH consensus project (2005) as including oral mucosal cGVHD, salivary hypofunction and sclerodermatous-like fibrosis of the peri-oral tissues. Oral cGVHD may also be associated with other lesions, including mucoceles, candidosis and the development of muco-fibrous pseudo membranes. 2 The degree of oral involvement with cGVHD can be extensive and often a source of significant pain, impairing alimentation, and thereby nutritional status, and impeding the maintenance of oral and dental health. 3 Although much is known about risk factors for acute and cGVHD, much less attention has been given to the specific factors that may predict oral GVHD in survivors of HCT. The aim of this study, therefore, was to assess the extent and range of oral long-term complications following allogeneic HCT and to explore potential risk factors for these adverse outcomes.
Materials and methods
Eighty-eight of 134 surviving patients (out of a total of 269 allogeneic HCT recipients) who were treated by the Westmead Hospital Blood and Marrow Transplant Unit (BMTU) during the period from January 2003 to July 2008 and who were at least 100 days post-transplant, agreed to participate in this study. Information, specifically the haematological diagnosis, donor type, stem cell source and conditioning regimen, was collected on each participant. The medical records were searched for previous diagnoses of acute complications of HCT, including mucositis and acute GVHD (aGVHD). Data were collated on all aspects of the transplant process to assess for risk factors for oral cGVHD, such as age at transplantation, mucositis, history of cGVHD and aGVHD. The grade (severity) of mucositis was based on the World Health Organisation criteria for common adverse events. 4 Late effects of HCT, including a diagnosis of cGVHD, were also gathered from the medical records, specifically the site and/ or organs involved and the presence and grade of oral manifestation of cGVHD. Analysis of this data allowed for the identification of potential risk factors associated with the development of oral complications of allogeneic HCT.
All subjects were interviewed using a standardised questionnaire, regarding their subjective assessment of any current oral complications possibly associated with HCT, including limitation in oral opening, impaired taste, diminished salivary function and increased dental decay rate. Subjects were asked to grade the severity of each of these symptoms of their oral GVHD as mild, moderate or severe and to grade, using the same terms, the cumulative impact of these oral adverse effects placed on their quality of life. Subjects were also asked about pre-transplant dental assessment and the regularity of post-transplant dental reviews, and to comment on the adequacy of any education material provided, pre-transplant, relating to the potential oral complications of HCT.
Participants then underwent a comprehensive clinical examination focused on the identification of objective evidence of the range of oral complications known to be associated with allogeneic HCT. The presence and location of mucosal pathology, including oral mucosal cGVHD and candidosis, were established using a dental mirror, gauze and overhead light. Any changes, including sclerodermatous microstomia, lichenoid lesions of cGVHD, and lesions suspicious for pre-malignancy/malignancy were described and the location was recorded diagrammatically (as detailed in Table 1 ). Dentition was only visibly inspected and no patients underwent dental imaging. Patients were then assessed as having none, mild, moderate or severe changes. Statistical analysis was carried out using the Pearson's w 2 -test and Fisher's exact test, where appropriate.
Results
A total of 64 (73%) participants had been diagnosed with cGVHD, with 56% (n ¼ 36) of subjects having documented oral involvement at some point after HCT. Patient characteristics are described in Table 2 . Of those with oral GVHD, 60% also had skin involvement, 64% hepatic, 58% gastrointestinal and 73% ocular GVHD. None were noted to have pulmonary GVHD. The most striking risk factor for oral GVHD was pre-existent aGVHD (74% vs 26%, P ¼ 0.015). There was also a statistically nonsignificant trend of a higher rate of oral GVHD with PBSCT relative to BMT (44% vs 29%; P ¼ 0.276).
At the time of examination, 47 subjects (53%) had evidence of oral adverse effects of transplantation. The most common oral complication identified was salivary gland hypofunction, with 34% (n ¼ 30) of subjects demonstrating some degree of hypofunction, the majority of whom (57%) had a severe reduction in salivary flow. A significant inverse association was seen between the time since HCT and the degree of salivary hypofunction (P ¼ 0.023), with only 44% of subjects 6 months to 2 years post-HCT having normal (45 mL) stimulated saliva quantities, compared with 88% of subjects who had normal salivary flow 5-6 years post-transplant. A clear trend was also evident between pre-existing aGVHD and the severity of salivary hypofunction (P ¼ 0.067), with those with a history of aGVHD demonstrating greater salivary hypofunction (53% vs 22 %) and a higher likelihood of severe hypofunction (28% vs 8%) relative to the subjects who did not have a preceding history of aGVHD.
Oral mucosal cGVHD was present in 21% of subjects at the time of examination (n ¼ 18). The clinical presentation was generally reticular in nature (67%); however, other clinical presentations of oral mucosal cGVHD were also seen ( Figure 1 ). The characteristics of oral mucosal cGVHD lesions in this population are described in Table 3 . More than one clinical pattern of mucosal oral cGVHD was seen in 39% of subjects at the time of examination. The likelihood of developing oral mucosal cGVHD was strongly associated with the stem cell source (P ¼ 0.051), with all those with oral mucosal cGVHD having received a PBSCT (n ¼ 18). Subjects who had received TBI were less likely to have oral mucosal cGVHD (P ¼ 0.051), with 9% (n ¼ 3) of subjects who had received TBI developing oral lichenoid lesions of cGVHD relative to 27% (n ¼ 15) of subjects who had not received TBI. Participants were also asked to describe any persistent oral symptoms they had following transplantation ( Figure 2 ). The most commonly reported adverse oral symptom was the sensation of oral dryness. In all, 44% of subjects (n ¼ 39) described xerostomia, with 44% of these subjects (n ¼ 17) grading their xerostomia as moderate to severe. No significant associations were found between xerostomia and with time since transplantation, history of aGVHD, stem cell source or type of HCT. In all, 20% of patients reported a persistent reduction in taste and 19% an accelerated rate of dental decay post-HCT, but only a minority, 15% (n ¼ 13) believed that these adverse oral changes significantly impacted on their overall quality of life.
The majority of subjects (80%) underwent a pretransplant dental exam. Aside from this routine pretransplant assessment, most patients had not been to a dentist in the previous year and even after HCT; the majority of subjects (n ¼ 44) still had infrequent dental reviews (41 year). Of this group, 57% (n ¼ 25) were unaware of the need for regular dental review, whereas 18% (n ¼ 8) found the cost of dental care prohibitive. Approximately half of the subjects were aware that longterm oral complications could occur after HCT (57%). The transplant physician was felt to be the most useful source of information about the potential oral complications of HCT (19%), whereas others obtained benefit from the BMTU Education Day (16%) and the patient-education book provided to BMT recipients to assist their preparation for admission for transplantation.
Discussion
The literature suggests that between 52 to 83% of patients diagnosed with cGVHD demonstrate some degree of oral involvement. 8 In this study, we found that of those who developed cGVHD, 56% had oral cGVHD and 
Table 3
Clinical features of oral mucosal cGVHD
Characteristics Most common Percentage Other sites

Oral sites involved
Buccal mucosa
Abbreviation: cGVHD ¼ chronic GVHD. Long-term oral complication after haematopoietic SCT KM Hull et al that the oral cavity was the second most commonly involved site (after the skin) affected by GVHD (skin 51%, oral cavity 41%).
There are a number of limitations to this study that may explain the lower than expected incidence of oral cGHVD. First, clinical diagnoses of cGVHD were derived from a retrospective review of each patient's medical recordmeaning that we relied upon accurate documentation by the medical team-something that could not be assumed, particularly as each patient may have been assessed by a number of different physicians following their transplant. In this regard, it is worth noting that implementation of the criteria proposed by the NIH Consensus Development Project on Criteria for Clinical Trials in Chronic GVHD for diagnosis and organ scoring may offer a means of standardising our assessment in the future. 2 Second, clinical assessment of oral GVHD was generally not confirmed histologically and clinical diagnosis was not standardised. Third, the retrospective nature of this study introduces the possibility of selection bias, as it included only survivors of HCT who agreed to participate in the study. Finally, the retrospective study design did not allow pre-transplant baseline measurements of mouth opening, dental health and salivary function, hence limiting the ability to ascribe such post-transplant findings, most notably salivary dysfunction, as being an adverse impact of HCT. The other potential limitation to this study is that our assessment of the impact of oral cGVHD on quality of life was assessed only by patients' self-reporting of this information and was not correlated with a more objective, validated measure of quality of life instrument such as the SF36 or the FACT-BMT. 9 Risk factors consistently associated with cGVHD include PBSCT, increased patient age, use of an unrelated donor, TBI and a preceding history of aGVHD. [10] [11] [12] The risk factors specific for the development of oral cGVHD are less well established; however, recent studies have described an association between oral GVHD and stem cell source, with an increased risk of oral GVHD in PBSCT (70%) relative to BMT (53%). 13 This association was also evident in our study, with a non-statistically significant trend suggesting that patients undergoing PBSCT had a higher prevalence of oral cGVHD (44%) relative to BMT (29%) and umbilical cord transplantation (25%). However, due to the very small study numbers of patients who underwent umbilical cord transplantation (n ¼ 4), this is unlikely to be a true representation of this group's risk for developing oral cGVHD. The major risk factor identified in this study was a history of aGVHD (P ¼ 0.015). We found no statistically significant association between oral cGVHD and the history or severity of transplant-associated mucositis, age at transplantation, TBI, the use of myeloablative conditioning or unrelated donor transplantation.
Oral mucosal cGVHD most commonly presents as lichenoid-like lesions-fixed, fine white striations with white hyperkeratotic plaques. Although almost any oral mucosal site may be involved, the sites most commonly reported in the literature include the buccal, glossal and labial mucosa. 14 In our study population, oral mucosal cGVHD lesions were diagnosed in 21% of subjects at the time of examination. Sites involved were consistent with those reported in the literature, with the vast majority involving the buccal mucosa (89%) followed by the lateral tongue (44%) and gingiva/alveolar mucosa (6%). Statistically significant associations were seen between oral mucosal cGVHD and the stem cell source, with all subjects who developed oral mucosal cGVHD having received PBSCT (n ¼ 18), a finding that is consistent with previously published studies. 15 Salivary gland dysfunction, which more typically arises in the acute stages following HCT, is predominately attributed to the conditioning regimen toxicity, especially the use of TBI and can persist for many months. Later changes are most often ascribed to cGVHD and clinically (and histologically) resemble the features of Sjo¨gren syndrome. 16 Extensive cGVHD involving the salivary glands results in destruction of secretory units, leading to a permanent and profound reduction in saliva production. 17 Reduced stimulated salivary flow, measured over 5 min, was the most consistently demonstrated adverse oral effect in this patient population, with 34% demonstrating some degree of salivary hypofunction. Severe hypofunction, measured as less than 3.5 mL produced over 5 min, was seen in 19% of subjects. A significant inverse association was seen between the time elapsed since transplantation and the prevalence of salivary hypofunction (P ¼ 0.023). This improvement in salivary function, post-transplantation is not well understood, but could represent a compensatory effect of salivary gland tissue less adversely affected by the conditioning regimen and/or acute or cGVHD. In this study, a correlation was also evident between previous aGVHD and the current severity of salivary hypofunction (P ¼ 0.067), with subjects who had a history of aGVHD having a higher proportion of severe hypofunction (28% vs 8%). Perhaps, surprisingly, we found no association between salivary hypofunction and the use of TBI (P ¼ 0.513) as part of the conditioning regimen.
Previous studies have documented xerostomia (the subjective complaint of oral dryness) as the second most distressing symptom reported by patients at discharge and at 1 year following haematopoietic SCT. 18 In this study, xerostomia was reported in 44% of subjects (n ¼ 39), with 44% (n ¼ 17) of these subjects grading their degree of xerostomia as moderate to severe. This sensation of oral dryness was not statistically associated with a history of TBI, and unlike patients with objective features of salivary hypofunction (reduction in mL/min), there was no association between time since transplantation (P ¼ 0.461) or a history of aGVHD (P ¼ 0.740). Only a minority, 15% (n ¼ 13), complained that xerostomia adversely impacted on their quality of life. This finding, in contrast to recent studies showing that moderate to severe xerostomia was associated with the poorest levels of overall health-related quality of life, 19 is difficult to explain but may relate to differences in measures used to assess xerostomia and quality of life.
It is generally recognised that xerostomia often does not correlate with objective clinical measurements of salivary hypofunction and, conversely, that a reduction in salivary flow may be clinically demonstrated in patients who do not otherwise complain of the sensation of a dry mouth, 20 a finding that was also observed in our study.
Only 10 of the 17 subjects who were categorised as having severe salivary hypofunction (o3.5 mL/measured over 5 min) self-reported a sensation of moderate to severe xerostomia, whereas six subjects who reported severe xerostomia had demonstrably normal salivary function (45 mL). Clinical history and the self-reporting of xerostomia, therefore, cannot be reliably used as a marker of salivary cGVHD. Other co-morbidities, including medications and anxiety, can also contribute to the sensation of xerostomia and/or salivary hypofunction and need to be considered. Sclerodermatous changes in the perioral tissues associated with cutaneous cGVHD may result in a reduced oral aperture, 21 potentially hindering alimentation, the maintenance of oral hygiene and the provision of dental care. The literature reports that the mean maximal unassisted opening falls in the range of 50-60 mm for normal, healthy individuals. 5, 6 Assessment of oral aperture in this population found that this was reduced in 42% of subjects, with 15 subjects demonstrating a moderate to severe reduction in opening. However, as pre-transplant assessment of oral opening was not undertaken and detailed clinical examination and imaging of the temporomandibular joints and associated muscles of mastication was outside of the scope of this study, the effect of pre-existing conditions, including myalgia of the muscles of mastication and arthralgia of the temporomandibular joint, could not be excluded, these result must be interpreted with caution.
The development of second malignancies and posttransplant lymphoproliferative disorders following HCT has long been recognised as a significant complication for long-term survivors of transplant, 22 with these patients having a 13-fold higher risk for developing second malignancies, including solid tumours such as oral squamous cell carcinoma. 23, 24 Oral squamous cell carcinomas were not diagnosed in any of our cohort, although given that the median time from HCT to solid tumour diagnosis is 7.0 years (range 0.9 to 22 years), with a cumulative incidence of 1.1% at 20 years. 25 The majority of our subjects had not survived for a sufficient period of time to be at high risk for oral squamous cell carcinoma.
The greater part of the study population were aware that long-term oral complications could occur after transplantation (57%); however, a significant proportion were unable to recall (16%) or were not aware of these complications (27%). Although most participants favoured pre-transplant delivery of this information, a significant proportion preferred that this information be given at their first outpatient review appointment following discharge (18%) or both pre-and post-transplantation (23%). This finding might suggest that rather than relying upon pre-admission patient education, repeated delivery of education and information about dental care in the outpatient setting post-transplant may be better received by patients and be more effective.
The oral cavity is frequently affected by cGVHD following allogeneic HCT, often coexisting with cutaneous, hepatic or ocular cGVHD. But, as seen in this study, can in its own right, lead to debilitating symptoms. Pre-existing aGVHD appears to be the major risk factor predicting the development of oral cGVHD, with time since transplantation predicting the degree of salivary hypofunction. Although PBSCT may increase the risk of oral GVHD (relative to BMT and UCB), this finding requires further validation in a larger study powered to detect associations with stem cell source and differences in conditioning regimens. The identification of risk factors specific for oral cGVHD may allow the identification of patients at high risk of developing oral cGVHD and provide a clear rationale for the institution of more frequent oral surveillance and rigorous preventative oral health strategies in this group.
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